Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 7/20 | 0.73 |
| ▸ | KCNA5 | P22460 | 7/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.73 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.70 |
| ▸ | MAOB | P27338 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7089852 | 1.00 | CYP2C19 (0.73) | CYP2C19KCNA5CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL23496077 | 1.00 | CYP2C19 (0.73) | CYP2C19KCNA5CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL9366911 | 0.98 | KCNA5 (0.74) | CYP2C19KCNA5CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL4875640 | 0.98 | KCNA5 (0.74) | CYP2C19KCNA5CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL4874914 | 0.83 | CYP3A4 (0.61) | CYP2C19KCNA5CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL23901671 | 0.83 | MAOB (0.51) | CYP2C19KCNA5CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL23901673 | 0.83 | CYP2D6 (0.59) | CYP2C19KCNA5CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL16226493 | 0.83 | KCNA5 (1.00) | CYP2C19KCNA5CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL16227210 | 0.83 | KCNA5 (1.00) | CYP2C19KCNA5CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL16227209 | 0.83 | KCNA5 (1.00) | CYP2C19KCNA5CYP3A4CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0915073-B1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE ISOMERS OF TRICYCLIC COMPOUNDS | TORAY INDUSTRIES (JP) | 2003-08-13 | — | — | EP | claimed |
| US-7335781-B2 | Aminothiol compound | HUEY JIIN CO., LTD. (TW) | 2008-02-26 | — | — | US | disclosed |
| US-7335781-B2 | Aminothiol compound | HUEY JIIN CO., LTD. (TW) | 2008-02-26 | — | — | US | disclosed |
| US-7335781-B2 | Aminothiol compound | HUEY JIIN CO., LTD. (TW) | 2008-02-26 | — | — | US | disclosed |
| US-20040236118-A1 | Pyrrolidine derivatives and method of synthesizing these | EIZAI CO., LTD (JP) | 2004-11-25 | — | — | US | disclosed |
| US-20040181057-A1 | perform as superior catalysts in asymmetric addition reactions wherein organic zinc and aldehyde are involved; Such catalyses are economically useful for industries | HUEY JIIN CO., LTD. (TW) | 2004-09-16 | — | — | US | disclosed |
| EP-1413574-A1 | PYRROLIDINE DERIVATIVES AND METHOD OF SYNTHESIZING THESE | Eizai Co., Ltd. (JP) | 2004-04-28 | — | — | EP | disclosed |
| EP-0915073-B1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE ISOMERS OF TRICYCLIC COMPOUNDS | TORAY INDUSTRIES (JP) | 2003-08-13 | — | — | EP | disclosed |
| US-6103914-A | Method of producing optically active material of tricyclic compound | TORAY INDUSTRIES, INC. (JP) | 2000-08-15 | — | — | US | disclosed |
| EP-0915073-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE ISOMERS OF TRICYCLIC COMPOUNDS | TORAY INDUSTRIES, INC. (JP) | 1999-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040236118-A1 | Pyrrolidine derivatives and method of synthesizing these | ADH1C, ADH5, ADH1A | CYP2C19 1076/4885KCNA5 4093/4885CYP3A4 245/4885 |
| US-20040181057-A1 | perform as superior catalysts in asymmetric addition reactions wherein organic zinc and aldehyde are involved; Such catalyses are economically useful for industries | ALDH7A1, ALDH3A1, ALDH1A1 | CYP2C19 1121/4885KCNA5 1478/4885CYP3A4 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.